Basic Information
Twinrix Adult
Regulatory Information
EMEA/H/C/000112
September 19, 1996
24
February 7, 2024
Company Information
Belgium
Rue de l'Institut, 89 B-1330 Rixensart
GlaxoSmithKline Biologicals SA
Active Substances Detail
hepatitis A virus (inactivated)hepatitis B surface antigen
hepatitis A virus (inactivated)
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection.
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).